HIGHLIGHTS
SUMMARY
Since the transmission of the infection usually occurs through an interaction between the viral spike (S) glycoprotein; a structural SARS-CoV-2 protein and a host cell receptor, such as the Angiotensin Converting Enzyme 2 (ACE 2); and the transmembrane serine protease type 2 (TMPRSS2), the development of monoclonal_antibodies (mAbs) targeting various epitopes of the S glycoprotein is considered an attractive therapeutic strategy. Most of the information on the efficacy of these neutralizing molecules is derived from in_vitro studies and contrasts with real-world data on the efficacy of sotrovimab. Wu et_al-based on . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.